Opioid Use Disorder Treatments: An Evidence Map

被引:1
|
作者
Sugarman, Allison [1 ]
Vittitow, Alexandria [1 ]
Cheng, Anna [1 ]
Malone, Mia [1 ]
McDonald, Ryan [1 ]
Pace, Nancy [1 ]
Williams, Ololade [1 ]
Tofighi, Babak [1 ,2 ]
McNeely, Jennifer [1 ,2 ]
Schatz, Daniel [1 ,2 ]
Roberts, Timothy [3 ]
Hey, Spencer Phillips [4 ,5 ]
Garrity, Kathleen [5 ]
Lindquist, Kristin [5 ]
Lee, Joshua D. [1 ,2 ,6 ]
机构
[1] NYU, Grossman Sch Med, Dept Populat Hlth, New York, NY USA
[2] NYU, Grossman Sch Med, Dept Med, New York, NY USA
[3] NYU, Grossman Sch Med, Hlth Sci Lib, New York, NY USA
[4] Harvard Med Sch, Ctr Bioeth, Boston, MA USA
[5] Prism Analyt Technol, Mt Pleasant, MI USA
[6] Dept Populat Hlth, 180 Madison Ave,17th Floor, New York, NY 10016 USA
关键词
Evidence map; Opioid use disorder; Buprenorphine; Methadone;
D O I
10.1016/j.drugalcdep.2022.109657
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Evidence maps are emerging data visualization of a systematic review. There are no published evidence maps summarizing opioid use disorder (OUD) interventions. Aim: Our aim was to publish an interactive summary of all peer-reviewed interventional and observational trials assessing the treatment of OUD and common clinical outcomes.Methods: PubMed, Embase, PsycInfo, Cochrane Central Register of Clinical Trials, and Web of Science were queried using multiple OUD-related MESH terms, without date limitations, for English-language publications. Inclusions were human subjects, treatment of OUD, OUD patient or community-level outcomes, and systematic reviews of OUD interventions. Exclusions were laboratory studies, reviews, and case reports. Two reviewers independently scanned abstracts for inclusion before coding eligible full-text articles by pre-specified filters: research design, study population, study setting, intervention, outcomes, sample size, study duration, geographical region, and funding sources.Results: The OUD Evidence Map (https://med.nyu.edu/research/lee-lab/research/opioid-use-disorder-treatmentevidence-map) identified and assessed 12,933 relevant abstracts through 2020. We excluded 9455 abstracts and full text reviewed 2839 manuscripts; 888 were excluded, 1591 were included in the final evidence map. The most studied OUD interventions were methadone (n = 754 studies), buprenorphine (n = 499), and naltrexone (n = 134). The most common outcomes were heroin/opioid use (n = 708), treatment retention (n = 557), and nonopioid drug use (n = 368). Clear gaps included a wider array of opioid agonists for treatment, digital behavioral interventions, studies of OUD treatments in criminal justice settings, and overdose as a clinical outcome.Conclusion: This OUD Evidence Map highlights the importance of pharmacologic interventions for OUD and reductions in opioid use. Future iterations will update results annually and scan policy-level interventions.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Opioid Use Disorder: Treatments and Barriers
    Patel, Karan
    Bunachita, Sean
    Agarwal, Ank A.
    Lyon, Aaron
    Patel, Urvish K.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [2] Cost-effectiveness of Treatments for Opioid Use Disorder
    Fairley, Michael
    Humphreys, Keith
    Joyce, Vilija R.
    Bounthavong, Mark
    Trafton, Jodie
    Combs, Ann
    Oliva, Elizabeth M.
    Goldhaber-Fiebert, Jeremy D.
    Asch, Steven M.
    Brandeau, Margaret L.
    Owens, Douglas K.
    JAMA PSYCHIATRY, 2021, 78 (07) : 767 - 777
  • [3] Opioid use disorder: current trends and potential treatments
    Lee, Yu Kyung
    Gold, Mark S.
    Blum, Kenneth
    Thanos, Panayotis K.
    Hanna, Colin
    Fuehrlein, Brian S.
    FRONTIERS IN PUBLIC HEALTH, 2024, 11
  • [4] Opioid Use Disorder: A Desperate Need for Novel Treatments
    Fuehrlein, Brian S.
    Ross, David A.
    BIOLOGICAL PSYCHIATRY, 2017, 81 (07) : E43 - E45
  • [5] Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality
    Kelty, Erin
    Hulse, Gary
    Joyce, David
    Preen, David B.
    CNS DRUGS, 2020, 34 (06) : 629 - 642
  • [6] Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality
    Erin Kelty
    Gary Hulse
    David Joyce
    David B. Preen
    CNS Drugs, 2020, 34 : 629 - 642
  • [7] Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date
    Reda M. Chalhoub
    Peter W. Kalivas
    Drugs, 2020, 80 : 1509 - 1524
  • [8] Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date
    Chalhoub, Reda M.
    Kalivas, Peter W.
    DRUGS, 2020, 80 (15) : 1509 - 1524
  • [9] Improving Translational Research Outcomes for Opioid Use Disorder Treatments
    Jones, Jermaine D.
    Varshneya, Neil B.
    Hudzik, Thomas J.
    Huhn, Andrew S.
    CURRENT ADDICTION REPORTS, 2021, 8 (01) : 109 - 121
  • [10] Improving Translational Research Outcomes for Opioid Use Disorder Treatments
    Jermaine D. Jones
    Neil B. Varshneya
    Thomas J. Hudzik
    Andrew S. Huhn
    Current Addiction Reports, 2021, 8 : 109 - 121